

# Accepted Manuscript

Investigating the prevalence, predictors and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome

Richard M. Turner, MB BChir, Peng Yin, PhD, Anita Hanson, BSc, Richard FitzGerald, MB ChB, Andrew P. Morris, PhD, Rod H. Stables, DM, Andrea L. Jorgensen, PhD, Munir Pirmohamed, PhD

PII: S1933-2874(16)30454-8

DOI: [10.1016/j.jacl.2016.12.007](https://doi.org/10.1016/j.jacl.2016.12.007)

Reference: JACL 1033

To appear in: *Journal of Clinical Lipidology*

Received Date: 17 June 2016

Revised Date: 6 December 2016

Accepted Date: 16 December 2016

Please cite this article as: Turner RM, Yin P, Hanson A, FitzGerald R, Morris AP, Stables RH, Jorgensen AL, Pirmohamed M, Investigating the prevalence, predictors and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome, *Journal of Clinical Lipidology* (2017), doi: 10.1016/j.jacl.2016.12.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Investigating the prevalence, predictors and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome

Richard M Turner<sup>1</sup> MB BChir

Peng Yin<sup>2</sup> PhD

Anita Hanson<sup>1</sup> BSc

Richard FitzGerald<sup>1</sup> MB ChB

Andrew P Morris<sup>2</sup> PhD

Rod H Stables<sup>3</sup> DM

Andrea L Jorgensen<sup>2</sup> PhD

Munir Pirmohamed<sup>1</sup> PhD

## Affiliations:

1. Department of Molecular & Clinical Pharmacology, University of Liverpool
2. Department of Biostatistics, University of Liverpool
3. Liverpool Heart and Chest Hospital

## Corresponding author:

Richard Turner

Wolfson centre for Personalised Medicine

University of Liverpool

Liverpool, UK

L69 3GL

Tel: +44 (0)151 7955407

Fax: +44 151 794 5059

Email: richard.turner@liverpool.ac.uk

Abstract word count: 243

Manuscript word count: 3,780

**Abstract**

**Background** High potency statin therapy is recommended in the secondary prevention of cardiovascular disease but discontinuation, dose reduction, statin switching and/or non-adherence occur in practice.

**Objectives** To determine the prevalence and predictors of deviation from high potency statin use early after a non-ST elevation acute coronary syndrome (NSTEMI-ACS), and its association with subsequent major adverse cardiovascular events (MACE) and all-cause mortality (ACM).

**Methods** 1,005 patients from a UK-based prospective NSTEMI-ACS cohort study discharged on high potency statin therapy (atorvastatin 80mg, rosuvastatin 20mg or 40mg daily) were included. At one month, patients were divided into constant high potency statin users, and suboptimal users incorporating statin discontinuation, dose reduction, switching statin to a lower equivalent potency and/or statin non-adherence. Follow up was a median 16 months.

**Results** There were 156 suboptimal (~15.5%) and 849 constant statin users. Factors associated in multivariable analysis with suboptimal statin occurrence included female sex (odds ratio (OR) 1.75, 95% confidence interval (CI) 1.14-2.68) and muscular symptoms (OR 4.28, 95% CI 1.30-14.08). Suboptimal statin use was associated with increased adjusted risks of time to MACE (hazard ratio (HR) 2.10, 95% CI 1.25-3.53,  $p=0.005$ ) and ACM (HR 2.46, 95% CI 1.38-4.39,  $p=0.003$ ). Subgroup analysis confirmed that the increased MACE/ACM risks were principally attributable to statin discontinuation/non-adherence.

**Conclusion** Conversion to suboptimal statin use is common early after NSTEMI-ACS, and is partly related to muscular symptoms. Statin discontinuation/non-adherence carries an adverse prognosis. Interventions that preserve and enhance statin utilisation could improve post NSTEMI-ACS outcomes.

**Key words**

Statin, cardiovascular, mortality, discontinuation, non-adherence, muscular symptoms

## Introduction

Cardiovascular disease (CVD) is the leading cause of mortality worldwide<sup>1,2</sup>. In the US and the UK, CVD accounts for the largest and second largest proportions of healthcare expenditure of any disease category, respectively<sup>3-5</sup>. Although an acute coronary syndrome (ACS) is a sudden event, most of the morbidity and mortality accrues later, following hospital discharge. Statins are 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitors that reduce circulating low-density lipoprotein-cholesterol (LDL-C). Following an ACS, high potency statin therapy, prescribed as atorvastatin 80mg daily, is indicated because it has been demonstrated in randomized controlled trials (RCTs) to be highly effective and superior to both placebo and moderate statin therapy for reducing cardiovascular events<sup>6-8</sup>. However, the effectiveness of drugs in RCTs can be undermined in clinical practice by several factors including poor adherence, discontinuation, and switching prescriptions to a lower equivalent potency. Poor statin adherence has been reported in up to 50% of patients<sup>9</sup>, statin discontinuation rates vary from 15%<sup>10</sup> to 60-75%<sup>11, 12</sup> and changing to lower potency statin therapy has been noted in ~1%<sup>13</sup> to 42%<sup>14</sup> of patients.

It is important to understand the clinical consequences of deviating from recommended high potency statin therapy in high-risk patients who have had at least one cardiovascular event. The adverse effects of statin non-adherence and discontinuation on cardiovascular clinical outcomes have been investigated previously<sup>15-17</sup>, but relatively little is known about the impact of statin dose reductions and/or switching to a statin of lower equivalent potency in real world secondary prevention<sup>14</sup>. The collective extent to which statin discontinuation, dose reduction, switching and/or non-adherence occur early in secondary prevention is also under-reported. Furthermore, few real world statin adherence studies have focussed exclusively on non-ST elevation ACS (NSTEMI-ACS) patients, which as a group are often older, have more comorbidities, are more likely to receive non-interventional medical management and have a worse long term prognosis than patients suffering an ST-elevation myocardial infarction (STEMI)<sup>18-20</sup> and so may be more susceptible to insufficient statin therapy.

Therefore, the aims of this study were to investigate: i) the prevalence of, ii) the risk factors for, and iii) the clinical consequences associated with conversion from high potency to 'suboptimal' statin use due to statin discontinuation, dose reduction, switching to an alternative statin of lower equivalent potency and/or statin non-adherence, early after an NSTEMI-ACS in a contemporary prospective cardiovascular cohort.

## **Material and methods**

### **Prospective study outline**

This investigation utilises a prospective CVD observational study that was conducted at 16 different UK hospital sites between 2008-2013, entitled the Pharmacogenetics of Acute Coronary Syndrome (PhACS). 1470 patients hospitalised with an NSTEMI-ACS (both non-ST elevation myocardial infarction (NSTEMI) and unstable angina) were eligible for inclusion in PhACS. Patients were followed up at one (visit 2 (V2)) and 12 months (visit 3 (V3)) post recruitment, and annually thereafter until all participants had been followed up for at least 12 months. Further study information is provided in the Supplement.

The protocol was approved by the Liverpool (adult) research Ethics Committee, UK; site-specific approval was granted at all sites involved and local informed consent was obtained from all study subjects in accordance with the Declaration of Helsinki.

### **Cohort Selection**

Patients were eligible for inclusion in the current study if they were discharged on a high potency statin from their index hospital NSTEMI-ACS admission. High potency statin therapy was: atorvastatin 80mg daily, the equivalently potent rosuvastatin 20mg, and rosuvastatin 40mg daily (see eTable 1 in the Supplement for relative potency information). All other statins and doses were considered non-high potency statin therapy. Patients were excluded if they died within 30 days of discharge, because this prevented assessment of suboptimal statin status during follow up (see below). Patients were excluded if their V2 occurred during a prolonged index hospital admission or did not actually occur until >180 days after

index admission (as ~85% of muscular symptoms occur within 180 days<sup>21</sup>), or they were lost to follow up following V2.

### **Assessment of statin adherence**

At V2, cardiac medication adherence was assessed using the Brief Medication Questionnaire (BMQ) (eFigure 1 in the Supplement)<sup>22</sup>. The BMQ incorporates three screens: a regimen screen, belief screen and a recall screen. The BMQ has been compared to the Medication Events Monitoring System.<sup>22</sup> The regimen screen had a sensitivity of 80% for detecting repetitive non-adherence and did not classify any adherent patients as non-adherent. However, it had 0% sensitivity for detecting sporadic non-adherence, and so its overall accuracy was 95%<sup>22</sup>. Further information about the BMQ is available in the Supplement. For the main analysis, assessment of adherence utilised the regimen screen; patients were classed statin non-adherent if they reported missing at least one statin pill over the past week.

### **Classification of suboptimal statin use**

Patients were designated 'suboptimal statin users' if, by V2, they had discontinued, reduced their statin dose, switched to an alternative statin of lower equivalent potency and/or were statin non-adherent. Patients that were on high potency statin therapy at baseline and V2 and were statin adherent represented 'constant statin users'.

### **Outcomes**

- i) Suboptimal statin use at V2 was itself the outcome for investigating clinical factors associated with its occurrence.
- ii) For investigating potential sequelae of suboptimal statin use, the primary endpoint was time to first major adverse cardiovascular event (MACE): a composite of death from a CVD (or no known) cause, or non-fatal myocardial infarction or ischaemic stroke. Time to all-cause mortality (ACM) was the secondary endpoint.

### Covariates

The following were considered for investigating factors associated with suboptimal statin occurrence: age  $\geq 75$ , sex, body mass index (BMI)  $\geq 30$ , hypertension, hyperlipidaemia, diabetes mellitus, smoking (current or previous versus non-smokers), chronic kidney disease, chronic obstructive pulmonary disease (COPD), prior CVD (previous MI, stroke, transient ischaemic attack (TIA) or peripheral artery disease (PAD)), statin use prior to index admission, raised index troponin, high potency statin discharged on (atorvastatin/rosuvastatin), treatment with PCI or CABG surgery during or within 30 days following discharge from index admission, New York Heart Association (NYHA) functional class at V2, reported use at V2 of aspirin, a P2Y<sub>12</sub> inhibitor, a beta blocker, an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker (ACEI/ARB), warfarin, or a proton pump inhibitor (PPI), concomitant use of levothyroxine (a surrogate for hypothyroidism) or a drug(s) that inhibits cytochrome P450 3A4 (CYP3A4) (listed in the Supplement), and muscular symptoms recorded at V2 (bothersome muscular pains/cramps/aches/weakness whilst on statin therapy recorded in the BMQ).

For the analyses investigating the risks of MACE and ACM, all of the above covariates were included except muscular symptoms, levothyroxine, CYP3A4-inhibiting drugs, and type of high potency statin discharged on. Follow up commenced from the date of V2.

### Subgroup analyses

Suboptimal statin use was divided into those who had discontinued or were statin non-adherent, and those who had reduced statin dose or switched statin (but were statin adherent), and the risks of time to MACE and ACM were analysed for both subgroups, compared to constant statin users.

### Statistical analysis

Overall, 4.3% of data were missing, but 28.6% of cases had at least one missing value. This missing data were handled as follows. First, missing V2 dates were imputed by adding 30 days to baseline discharge date, because 30 days represented the median duration of the non-missing data. Second, V2 drug data were manually imputed where possible by comparison of baseline and V3 drug data. Missing V2 muscular symptoms were also manually imputed as 'no symptoms', because only 1.2% of patients openly reported symptoms. Lastly, multiple imputation was used: all remaining missing values were sampled using a fully conditional specification method, which uses an iterative Markov chain Monte Carlo procedure, and ten imputation datasets were generated. See the Supplement for further details.

i) **Investigating factors associated with suboptimal statin use**

Following imputation, the null hypothesis of no association with suboptimal statin occurrence (compared to constant statin use) was tested for each variable using the Wald test, because it generates a pooled value from the ten datasets. Those covariates with univariate  $p < 0.1$  were entered into a multivariable logistic regression model, using forwards stepwise (likelihood ratio) selection. Odds ratios (OR) and p-values are pooled from the ten imputed datasets;  $p < 0.05$  indicated significance.

ii) **Investigating risks of MACE and ACM associated with suboptimal statin use**

A univariate Cox proportional hazard model was fitted for each covariate to test its association with time to MACE; the same was performed for time to ACM. For each covariate, the Cox proportional hazards assumption was assessed by visual inspection of Kaplan-Meier curves. If a covariate did not meet the proportional hazards assumption, it was excluded from the main analyses (see sensitivity analyses D1 and D2). Covariates meeting the proportional hazards assumption and  $p\text{-value} < 0.1$  in univariate analysis were taken forwards into multivariable Cox proportional hazards modelling, with the final multivariable model covariates chosen by forwards stepwise (likelihood ratio) selection. After the covariate model had been fitted for both time to MACE and time to ACM, suboptimal statin use was introduced into both models to test its adjusted association with risk of MACE, or ACM. The hazard ratios (HR) and p-values provided in the results section are pooled results across all imputed datasets, except in the complete cases sensitivity analyses.



As two outcomes (MACE, ACM) were investigated here, a Bonferroni correction was used to adjust the significance threshold to  $p \leq 0.025$ . This threshold was also applied to all sensitivity analyses that further examined the risks of MACE or ACM associated with suboptimal statin use (see below).

### **Sensitivity Analyses**

To investigate result robustness, sensitivity analyses were undertaken (see the Supplement for details). Firstly, a subcohort consisting of all cases with complete data ('complete cases') assessed whether missing data impacted either the factors associated with suboptimal statin occurrence or the associations between suboptimal statin use and risk of MACE/ACM. Additional sensitivity analyses evaluated the robustness of the associations between suboptimal statin use and MACE/ACM further by: expanding the statin non-adherence definition, considering covariates that did not meet the proportional hazards assumption for full follow up duration, including all variables that differed significantly between suboptimal and constant statin user groups at V2, and examining the potential for healthy user bias by considering PPI prescription changes between baseline discharge and V2.

The expanded statin non-adherence definition was: patients that missed at least one statin pill (BMQ Qu. 1e), took a statin for six or fewer days (Qu. 1b) (both from regimen screen), reported that the statin did not work well for them or they did not know (Qu. 1g), found that the statin bothered them at least a little (Qu. 2) (both from belief screen) and those that found it at least somewhat hard to remember to take all of their pills (Qu. 3c the recall screen).

All analyses were performed using IBM SPSS version 22.0 (IBM Corp, Armonk, NY, USA).

## Results

Figure 1 outlines the cohort selection process for this study. 1,005 patients discharged on a high potency statin were included; >99% were prescribed atorvastatin 80mg daily. 156 patients (15.5%) were suboptimal statin users by V2; 849 (84.5%) remained on and adherent to high potency statin therapy, constituting constant statin users.

Of 1005 eligible patients discharged from hospital with a diagnosis of non-ST elevation acute coronary syndrome on recommended high potency statin therapy, 156 (15.5%) had inadequate statin utilisation by a median of one month following hospital discharge; 849 (84.5%) patients remained on and adherent to high potency statin therapy at V2.

### Factors associated with suboptimal statin occurrence

Suboptimal and constant statin users were broadly similar (Table 1). However, in multivariable logistic regression, being female ( $p=0.010$ ), not on either a P2Y<sub>12</sub> inhibitor ( $p=0.007$ ) or beta blocker at V2 ( $p=0.036$ ), and being bothered by muscular symptoms ( $p=0.017$ ) were all associated with an increased adjusted risk of suboptimal statin occurrence (Table 2).

**Table 1** Characteristics of suboptimal and constant statin users

Variable	Suboptimal Statin therapy	Constant Statin users	Unadjusted p-value
<b>Patients (%)</b>	156 (15.6)	849 (84.4)	
Median follow up from V2 (months)	16	15	0.52
<b>Demographics</b>			
Age $\geq$ 75, n (%)	39 (25.0)	161 (19.0)	0.13
Men, n (%)	102 (65.4)	660 (77.4)	0.004
BMI $\geq$ 30, n (%)	54 (34.6)	292 (33.4)	0.92
<b>Medical History, n (%)</b>			
Hypertension	93 (59.6)	490 (57.7)	0.63
Hyperlipidaemia	75 (48.1)	455 (53.6)	0.27
Diabetes mellitus	43 (27.6)	43 (27.6)	0.091
Ever smoked	113 (72.4)	588 (69.3)	0.42
CKD (Cr $>$ 150 $\mu$ mol/L)	13 (8.3)	48 (5.7)	0.28
COPD	13 (8.3)	74 (8.7)	0.89
Prior CVD <sup>1</sup>	51 (32.7)	287 (33.8)	0.82
On Statin prior to index admission	79 (50.6)	387 (45.6)	0.30
<b>Diagnosis, n (%)<sup>2</sup></b>			
Troponin-raised NSTEMI-ACS	149 (95.5)	828 (97.5)	0.16
Normal troponin NSTEMI-ACS	7 (4.5)	21 (2.5)	-
<b>Treatment, n (%)</b>			
PCI/CABG	72 (46.2)	401 (47.2)	0.80
Discharged on Atorvastatin 80mg daily	155 (99.4)	843 (99.3)	0.91
<b>NYHA Functional Classification at Visit 2, n (%)</b>			
Class I	82 (52.6)	457 (53.8)	0.61
Class II	56 (35.9)	314 (37.0)	
Class III	18 (11.5)	70 (8.3)	
Class IV	0 (0.0)	8 (0.9)	
<b>Drugs at Visit 2, n (%)</b>			
Aspirin	142 (91.0)	795 (93.6)	0.36
P2Y <sub>12</sub> inhibitor	122 (78.2)	738 (86.9)	0.006
Beta blocker	119 (76.3)	725 (85.4)	0.016
ACEI/ARB	121 (77.6)	706 (83.2)	0.11
Warfarin	6 (3.9)	41 (4.8)	0.57
Proton pump inhibitor	67 (43.0)	358 (42.2)	0.89
CYP3A4-inhibitors	19 (12.2)	66 (7.8)	0.080

Levothyroxine	6 (3.8)	39 (4.6)	0.67
<b>Muscular symptoms at V2, n (%)</b>	5 (3.2)	7 (0.8)	0.020

ACEI = angiotensin converting enzyme inhibitor; ARA = aldosterone receptor antagonist; ARB = angiotensin II receptor blocker; BMI = body mass index; CABG = coronary artery bypass graft surgery; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; Cr = creatinine; CVD = cardiovascular disease; CYP3A4 = cytochrome P450 3A4 drug-metabolising enzyme; LD = loop diuretic; NSTE-ACS = non-ST elevation acute coronary syndrome; PCI = percutaneous coronary intervention; V2 = Visit two.

<sup>1</sup> = Prior CVD encompasses past MI, stroke, TIA or PAD; <sup>2</sup> = raised troponin taken to indicate non-ST elevation myocardial infarction (NSTEMI), and a normal troponin unstable angina.

**Table 2** Adjusted factors associated with suboptimal statin occurrence

Risk factor	Suboptimal Statin therapy, n (%)	Constant Statin users, n (%)	Multivariable analysis	
			OR (95% CI)	p-value
Muscular symptoms	5 (3.2)	7 (0.8)	4.28 (1.30-14.08)	0.017
Sex (F vs M)	M: 102 (65.4)	M: 660 (77.4)	1.75 (1.14-2.68)	0.010
P2Y <sub>12</sub> inhibitor at V2	122 (78.2)	738 (86.9)	0.53 (0.34-0.84)	0.007
Beta blocker at V2	119 (76.3)	725 (85.4)	0.59 (0.36-0.96)	0.036

Covariates with univariate  $p < 0.1$  were entered into multivariable logistic regression modelling using a forwards likelihood ratio method to select the multivariable model presented here.

### Risks of MACE and ACM associated with suboptimal statin use

The median study duration after V2 was 16 months, and there were 113 MACE and 79 ACM events; 33% of ACM deaths were non-cardiovascular. Table 3 shows the results of the univariate analyses of association between time to MACE, or time to ACM, and each variable considered. Of patients with suboptimal statin use, 32 and 25 suffered MACE and ACM, respectively. In multivariable analysis, suboptimal statin use was a risk for both time to MACE (HR 2.10, 95% confidence interval (CI) 1.25-3.53,  $p=0.005$ ) and time to ACM (HR 2.46, 95% CI 1.38-4.39,  $p=0.003$ ), after adjusting for age  $\geq 75$ , prior CVD, PCI/CABG treatment, NYHA class, and either diabetes mellitus (time to MACE) or chronic kidney disease (time to ACM) (Table 4). The adjusted survival curves, stratified by suboptimal statin status, are illustrated in Figures 2A and 2B, and demonstrate early separation of hazard risk after V2.

**Table 3** Univariate Cox regression analysis results for association with time to MACE or time to ACM.

Variable	Time to MACE (n=113)		Time to ACM (n=79)	
	HR (95% CI)	p-value	HR (95% CI)	p-value
<b>Demographics</b>				
Age $\geq$ 75	3.02 (2.07-4.40)	<0.001	5.17 (3.31-8.07)	<0.001
Sex (F vs M)	1.31 (0.87-1.97)	NS (p=0.19)	*	*
BMI $\geq$ 30	1.30 (0.89-1.90)	NS (p=0.18)	1.40 (0.89-2.20)	NS (p=0.14)
<b>Medical History</b>				
Hypertension	1.82 (1.21-2.71)	0.004	2.12 (1.29-3.49)	0.003
Hyperlipidaemia	1.56 (1.06-2.27)	0.023	1.90 (1.20-3.02)	0.007
Diabetes mellitus	2.56 (1.76-3.74)	<0.001	2.77 (1.78-4.33)	<0.001
Ever smoked	1.22 (0.80-1.86)	NS (p=0.35)	1.33 (0.80-2.21)	NS (p=0.27)
CKD (Cr>150)	2.72 (1.65-4.47)	<0.001	3.93 (2.34-6.61)	<0.001
COPD	1.39 (0.79-2.43)	0.26	1.88 (1.03-3.42)	0.039
Prior CVD	3.06 (2.09-4.48)	<0.001	4.25 (2.64-6.87)	<0.001
On statin prior to index admission	1.66 (1.14-2.42)	0.009	2.01 (1.26-3.21)	0.003
<b>Diagnosis</b>				
Raised vs normal troponin NSTEMI-ACS	0.84 (0.34-2.09)	NS (p=0.71)	1.47 (0.36-6.01)	NS (p=0.59)
<b>Treatment</b>				
PCI/CABG	0.42 (0.28-0.63)	<0.001	0.31 (0.18-0.53)	<0.001
<b>Functional statin at V2</b>				
NYHA	1.89 (1.51-2.37)	<0.001	2.07 (1.60-2.70)	<0.001
<b>Drugs at V2</b>				
Suboptimal Statin therapy	2.18 (1.40-3.40)	0.001	2.54 (1.56-4.14)	<0.001
Aspirin	0.49 (0.28-0.86)	0.013	0.23 (0.13-0.38)	<0.001
P2Y <sub>12</sub> inhibitor	*	*	0.66 (0.39-1.12)	NS (p=0.12)
Beta blocker	0.86 (0.53-1.42)	NS (p=0.56)	0.76 (0.43-1.34)	NS (p=0.34)
ACEI/ARB	1.46 (0.84-2.55)	NS (p=0.18)	1.16 (0.63-2.13)	NS (p=0.63)
Warfarin	2.23 (1.13-4.42)	0.022	2.94 (1.41-6.13)	0.004
Proton pump inhibitor	0.97 (0.67-1.42)	NS (p=0.89)	1.40 (0.90-2.18)	NS (p=0.14)

\* = Visit two P2Y<sub>12</sub> status did not meet the proportional hazards assumption for MACE, and patient sex did not meet the proportional hazards assumption for ACM; these variables were considered in sensitivity analyses (see eTables 5, 8, 9 in the Supplement).

**Table 4** Multivariable adjusted Cox regression results for risk of time to MACE or ACM

Variable	Time to MACE		Time to ACM	
	HR (95% CI)	p-value	HR (95% CI)	p-value
<b>Suboptimal Statin therapy</b>	<b>2.10 (1.25-3.53)</b>	<b>0.005</b>	<b>2.46 (1.38-4.39)</b>	<b>0.003</b>
Age $\geq$ 75	2.05 (1.36-3.09)	0.001	3.47 (2.12-5.68)	<0.001
NYHA	1.48 (1.12-1.96)	0.006	1.62 (1.16-2.27)	0.005
Treatment with PCI/CABG	0.56 (0.37-0.86)	0.008	0.49 (0.28-0.85)	0.011
Prior CVD	2.00 (1.31-3.04)	0.001	2.43 (1.45-4.08)	0.001
Diabetes mellitus	1.52 (1.002-2.30)	0.049	-	-
Chronic kidney disease	-	-	1.65 (0.93-2.93)	0.089

Covariates with  $p < 0.1$  in univariate Cox analysis were entered into multivariable Cox regression modelling using the forwards likelihood ratio method to select the covariate model (variables not in bold font). After these time to MACE or ACM covariate models were selected, the suboptimal statin therapy variable was entered into both models to produce the presented results.

### Sub-group analyses

The subgroup of suboptimal statin users that had discontinued/were non-adherent ( $n=95$ ) had significantly increased risks of MACE (HR 2.74 (1.49-5.04,  $p=0.001$ ) and ACM (HR 3.50 (1.69-7.23,  $p=0.001$ ), compared to constant statin users (Table 5). The smaller subgroup of patients with reduced statin dose/switched statin ( $n=61$ ), did not have significantly increased risks of MACE ( $p=0.24$ ) or ACM ( $p=0.22$ ) (Table 5).

**Sensitivity Analyses** Complete cases subcohort sensitivity analyses reinforce that muscular symptoms, female sex and beta blocker use were associated with suboptimal statin occurrence (eTables 2, 3 in the Supplement). Suboptimal statin use was robustly associated with risks of MACE, and ACM, irrespective of adherence definition (Table 5), missing data imputation (Table 5, and eTable 5 in the Supplement), variables that did not meet the proportional hazards assumption (P2Y<sub>12</sub> use for MACE and sex for ACM) and after inclusion of all variables associated with suboptimal statin occurrence (eTables 5-9 in the Supplement). There was no substantive healthy user effect (eTables 5, 10, 11 in the Supplement).

**Table 5** Summary of main results for the adjusted risks of time to MACE or ACM associated with suboptimal statin use

Analysis	Statin use, n (%)		Time to MACE		Time to ACM	
	Suboptimal	Constant	HR (95% CI)	p-value	HR (95% CI)	p-value
<b>Main Analysis</b>	156 (15.5)	849 (84.5)	2.10 (1.25-3.53) <sup>1</sup>	0.005	2.46 (1.38-4.39) <sup>2</sup>	0.003
<b>Subgroup analyses:</b>						
Statin discontinuation/ non-adherence only	95 (10.1)	849 (89.9)	2.74 (1.49-5.04) <sup>3</sup>	0.001	3.50 (1.69-7.23) <sup>4</sup>	0.001
Statin dose reduction/ switch only	61 (6.7)	849 (93.3)	1.55 (0.75-3.20) <sup>5</sup>	0.24	1.71 (0.72-4.04) <sup>6</sup>	0.22
<b>Main Sensitivity analyses:</b>						
Including expanded non- adherence definition	272 (27.1)	733 (72.9)	1.75 (1.17-2.63) <sup>7</sup>	0.007	1.75 (1.06-2.89) <sup>8</sup>	0.030
Complete cases analysis	89 (12.3)	635 (87.7)	2.60 (1.58-4.28) <sup>9</sup>	<0.001	3.41 (1.91-6.06) <sup>10</sup>	<0.001

For each analysis (main, subgroup and sensitivity analyses for both time to MACE and time to ACM), a multivariable covariate model was fitted before the suboptimal statin variable was added. Covariates with univariate  $p < 0.1$  were entered into multivariable Cox proportional hazards modelling, with the final multivariable covariate model for each analysis chosen by forwards stepwise (likelihood ratio) selection. All analyses selected to adjust for age  $\geq 75$ , prior cardiovascular disease (previous myocardial infarction, stroke, transient ischaemic attack or peripheral artery disease), New York Heart Association functional class at Visit 2 and treatment with percutaneous coronary intervention or coronary artery bypass grafting surgery during baseline admission or within 30 days of discharge. Other covariates adjusted for in specific analyses were: diabetes mellitus (analyses 1, 6, 7, 9, 10); chronic kidney disease (analyses 2, 3, 4, 8).

## Discussion

The main findings of this study are firstly, by a median of one month after admission for NSTEMI-ACS in patients discharged on high potency statin therapy, ~15% have suboptimal statin utilisation. Expanding the non-adherence definition increased this to 27% (Table 5). Secondly, suboptimal statin occurrence was associated with muscular symptoms, female sex, and reduced use of beta blockers and P2Y<sub>12</sub> inhibitors. Thirdly, suboptimal statin use was associated with increased adjusted risks of times to both MACE and ACM, although this was largely attributable to statin discontinuation/non-adherence early after NSTEMI-ACS rather than statin dose reduction/statin switching.

This study is novel because it considered all components of attenuated statin therapy (discontinuation, non-adherence, switching and dose reduction), both collectively and in subgroups. To date, the majority of adherence studies have assessed medication availability (e.g. proportion of days covered) via electronic data sources<sup>23-25</sup>. Although this approach allows assessment of average adherence over time, it is difficult for healthcare professionals to easily measure and act upon in practice. Importantly, the pragmatic approach used in this study highlights the importance of assessing statin usage early after hospital discharge in CVD secondary prevention patients. Furthermore, the assessment of statin utilisation used in this study is relatively straightforward and so is potentially actionable.

Overall, there were few differences at V2 between suboptimal and constant statin users. However interestingly, females<sup>23, 24, 26, 27</sup> and a lower rate of beta blocker<sup>23, 28</sup> and antiplatelet<sup>29</sup> drug use have all previously been associated with poorer statin adherence. In this study, suboptimal statin users were more likely to have not been prescribed P2Y<sub>12</sub> therapy at hospital discharge and to have stopped the beta blocker they were discharged on (data not shown). This study also found that muscular symptoms were a risk factor for suboptimal statin use. Very few other statin utilisation studies have included potential adverse events, although a cross-sectional internet-based survey previously determined that muscular symptoms are reported more frequently in patients that have discontinued, switched statin or are non-adherent, compared to non-switching statin adherent participants<sup>27</sup>. Overall, there was no evidence that these differences altered the multivariable increased risks of time to MACE or ACM associated with suboptimal statin use (eTables 8 and 9 in the Supplement).

Statins are associated with increased myotoxicity, incident diabetes mellitus and probably haemorrhagic stroke<sup>30</sup>. Statin-associated muscular symptoms are reported in ~1.5-3% of statin users in RCTs<sup>31</sup> and in ~7-29% of patients in observational studies<sup>32</sup>. However, whilst rare statin-induced severe myopathy/rhabdomyolysis is incontrovertible, the contribution of statins to milder muscle symptoms remains controversial. One informative estimate for the extent of muscular symptoms *attributable* to statin therapy is ~5%<sup>33</sup>, which is derived from a



blinded RCT that compared rates of stringently defined myalgia in healthy volunteers receiving either atorvastatin 80mg daily or placebo for six months ( $p=0.05$ )<sup>33</sup>. The reported rate of bothersome muscular symptoms in our observational study was low (~1.2%) (Table 1). This may be a reflection of muscular symptoms not being explicitly asked about, and/or because patients who experienced muscular symptoms shortly after discharge had amended their statin therapy by V2, with potential symptomatic resolution. There is currently no unifying mechanistic explanation for statin-induced myotoxicity. However, several factors increase risk including female sex, advanced age, hypothyroidism, chronic kidney disease, exercise, drug-drug interactions, and for simvastatin myopathy specifically a genetic variant (*SCLO1B1* rs4149056) is a risk factor<sup>34</sup>.

The largest type of suboptimal statin users in this study was statin non-adherent patients. The aetiology of statin non-adherence is multifactorial and incompletely understood; predictors beyond those identified in this study include age, low income and increased non-cardiovascular medications<sup>35</sup>. Health beliefs and knowledge affect both perceptions of need for a treatment, and counteracting perceptions of potential treatment adverse effects, are influenced by factors such as patient satisfaction with physician treatment explanations, and likely also modulate non-adherence<sup>36</sup>. Therefore, irrespective of the exact underlying aetiology of mild muscular symptoms, the attribution of these symptoms to statin therapy by a patient will potentially reduce statin utilisation.

Another potential reason for the statin discontinuation/dose reductions/statin switching observed in this study early after an NSTEMI-ACS is a communication breakdown leading to the high potency statin hospital discharge prescription not being transferred and incorporated into a patient's repeat outpatient prescription drug list. Transfer of medical information from secondary to primary care is often incomplete and untimely<sup>37, 38</sup>, although further research is required to evaluate the extent of its potential impact on early post-ACS suboptimal statin therapy.

Previous secondary prevention cohorts have reported elevated risk estimates for statin non-adherence or discontinuation/persistence of 1.01-5.26 for MACE and 1.25-5.00 for

mortality, with the majority reporting statistically significant results<sup>39</sup>. Our study results of increased adjusted risks of time to MACE or ACM associated with both suboptimal statin use and the statin non-adherence/discontinuation subgroup in particular are in keeping with these findings. This emphasises the generalizability of these clinically relevant findings across secondary prevention populations, settings and study designs.

In this study of NSTEMI-ACS patients, the statin dose reduction/switching statin subgroup was not significantly associated with increased risks of time to MACE or ACM. One other prospective study has investigated statin dose reduction/switching following ACS, but included both NSTEMI-ACS and ST-elevation ACS patients, and reported a significantly increased risk for adverse clinical outcomes (HR 2.7, 95% CI 1.7-5.1)<sup>14</sup>. Our smaller number of dose reduction/switching cases (n=61) may have accounted for this subgroup only showing a non-significant trend for increased risk. Two other observational studies have investigated the influence of switching from atorvastatin to simvastatin<sup>40, 41</sup> on cardiovascular events, using mixed primary/secondary prevention populations identified using electronic healthcare databases. The UK-based study found a modestly increased cardiovascular event risk (HR 1.30, 95% CI 1.02-1.64)<sup>40</sup>, whilst the US-based study found no association<sup>41</sup>. However in both of these studies the majority of patients were on atorvastatin  $\leq 20$ mg/day, and it has been noted that the proportion of switches from atorvastatin to a lower rather than equivalently potent simvastatin regimen increases as the initial atorvastatin dose increases<sup>41</sup>. This is particularly relevant in post-ACS patients, as practically all switches from atorvastatin 80mg/day are to another statin of lower equivalent potency. Overall, persistent adherence to high potency statin therapy after an ACS appears optimal; however, if necessary, reducing the dose or switching statin appears preferable to statin non-adherence or complete discontinuation.

Recently, several interventions have been proposed that attempt to reduce non-adherence/discontinuation and improve statin therapeutic effectiveness, including improving CVD and statin literacy, co-payment reduction, using fixed-dose 'polypill' combinations and behaviour-modification interventions<sup>17</sup>. For example, brief pharmacist-led face-to-face counselling sessions have been shown to improve statin adherence<sup>42</sup>. There is also increasing interest in utilising mobile technology applications (apps) to remind patients to

take their medications, and patients are being involved in medication-related app development<sup>43</sup>. It is thus plausible that an intervention based on reminders (e.g. apps and/or posted letters) and face-to-face contact could be targeted to patients early after a CVD event to both screen for and address suboptimal statin utilisation, although further research is required.

Our study has limitations. It is a *post hoc* assessment of the PhACS study. The exact reasons for statin prescription changes and the cause(s) for patient non-adherence were not recorded. The data are observational and therefore we cannot confirm causality due to the potential for confounding influences by unmeasured variables, such as cardiac rehabilitation attendance. Although we cannot definitively exclude any healthy user effect, our assessment of PPI utilisation (eTables 10 and 11 in the Supplement) is in keeping with the lack of healthy user effect reported in other statin utilisation studies<sup>23, 24, 44</sup>, and so makes a prominent contribution of this type of influence unlikely. It is acknowledged that both the assessment of statin adherence at a single time point and basing the primary assessment on the number of pills missed over the preceding week will limit detection of sporadic non-adherence<sup>22</sup>. However, the expanded non-adherence definition (Table 5) includes all components of the BMQ and the BMQ recall screen (enquiring about how hard the patient finds it to remember to take all the pills) has a sensitivity of 90% for sporadic non-adherence, albeit with a reduced specificity of 80%<sup>22</sup>. The assessment of statin utilisation at one month is also unlikely long enough to capture full stabilisation of drug use. However, median statin discontinuation in secondary prevention appears to occur at 30-37 days after discharge<sup>14, 45</sup>, and our approach does not preclude follow up adherence assessments. Overall, this investigation used a prospective multicentre study with event validation rather than electronic diagnostic codes, and the several sensitivity analyses confer robustness to the main findings.

In conclusion, patients with an NSTEMI-ACS are at high risk of subsequent MACE and ACM. Following discharge on high potency statin therapy, the intensity of statin therapy is already reduced for a sizeable proportion of patients by one month back in the community, and self-reported muscular symptoms appear to increase the risk for suboptimal statin utilisation. Early statin discontinuation/non-adherence correlates with increased risks of subsequent

MACE and ACM. Physicians, pharmacists and cardiac rehabilitation programmes are encouraged to discuss statin therapy with ACS patients early after discharge, reaffirm the benefits of statins, and explore barriers to their effective use in order to maintain and enhance statin utilisation and so potentially improve post NSTEMI-ACS outcomes.

## Acknowledgements

### Author Contributions:

*Prospective Study and design:* Pirmohamed, FitzGerald, Hanson, Jorgensen, Stables.

*Acquisition, analysis, or interpretation of data:* All authors.

*Statistical analysis:* Turner, Jorgensen, Morris, Yin.

*Drafting of manuscript:* Turner.

*Critical revision of the manuscript:* All authors.

All authors have approved the final manuscript.

**Conflict of Interest Disclosure:** All authors declare no conflicts of interest.

**Funding/Support:** The clinical study was funded as part of the NHS Chair of Pharmacogenetics, Department of Health. RMT is supported by the NW England MRC Training Scheme in Clinical Pharmacology. The authors also wish to thank the MRC Centre for Drug Safety Science for Support. MP is a NIHR Senior Investigator. APM is a Wellcome Trust Senior Fellow in Basic Biomedical Science (grant number WT098017).

**Additional Contributions:** Mr Jon Cresswell BSc (Hons), senior data manager, set up and managed the study database. The Wolfson Centre for Personalised Medicine, University of Liverpool, UK, L69 3GL.

## References

- 1 World Health Organisation. The top 10 causes of death. 2014 [cited 2016 04 May]; Available from: <http://www.who.int/mediacentre/factsheets/fs310/en/>
- 2 World Health Organisation. Global status report on noncommunicable diseases 2014. 2014 [cited 2016 04 May]; Available from: [http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1)
- 3 Cohen JW, Krauss NA. Spending and service use among people with the fifteen most costly medical conditions, 1997. *Health Aff (Millwood)*. 2003 Mar-Apr;22(2):129-38.
- 4 Nuffieldtrust. NHS spending on the top three disease categories in England. 2014 [cited 2016 04 May]; Available from: <http://www.nuffieldtrust.org.uk/data-and-charts/nhs-spending-top-three-disease-categories-england>
- 5 Twaddle S, Marshall M, Michael N. Programme Budgeting - Testing the Approach in Scotland. 2012 [cited 2016 04 May]; Available from: <http://www.gov.scot/Resource/0039/00391293.pdf>
- 6 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*. 2004 Apr 8;350(15):1495-504.
- 7 Waters D, Schwartz GG, Olsson AG. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins? *Curr Control Trials Cardiovasc Med*. 2001;2(3):111-4.
- 8 Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. *Drugs*. 2007;67 Suppl 1:29-42.
- 9 Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. *Can J Cardiol*. 2005 May 1;21(6):485-8.
- 10 Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? *N Engl J Med*. 1995 Apr 27;332(17):1125-31.
- 11 Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. *Jama*. 2002 Jul 24-31;288(4):455-61.
- 12 Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. *Med J Aust*. 1996 Feb 19;164(4):208-11.
- 13 Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. *Am J Manag Care*. 2007 Jun;13 Suppl 3:S80-5.
- 14 Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. *Int J Cardiol*. 2011 Oct 6;152(1):56-60.
- 15 Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. *Eur Heart J*. 2013 Oct;34(38):2940-8.
- 16 Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. *Curr Pharm Des*. 2011 Nov;17(33):3669-89.
- 17 Phan K, Gomez YH, Elbaz L, Daskalopoulou SS. Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions. *Curr Pharm Des*. 2014;20(40):6314-24.
- 18 Docherty A. Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTEMI) in older patients. *Arch Gerontol Geriatr*. 2010 Sep-Oct;51(2):129-34.
- 19 De Luca L, Leonardi S, Cavallini C, et al. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. *Eur Heart J Acute Cardiovasc Care*. 2014 Nov 20.
- 20 Garcia-Garcia C, Subirana I, Sala J, et al. Long-term prognosis of first myocardial infarction according to the electrocardiographic pattern (ST elevation myocardial infarction, non-ST elevation myocardial infarction and non-classified myocardial infarction) and revascularization procedures. *Am J Cardiol*. 2011 Oct 15;108(8):1061-7.
- 21 Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. *Cardiovasc Drugs Ther*. 2005 Dec;19(6):403-14.
- 22 Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. *Patient Educ Couns*. 1999 Jun;37(2):113-24.
- 23 Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. *Jama*. 2007 Jan 10;297(2):177-86.
- 24 Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. *Am Heart J*. 2008 Apr;155(4):772-9.
- 25 Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. *Br J Clin Pharmacol*. 2008 Jul;66(1):110-6.
- 26 Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. *Arch Cardiovasc Dis*. 2010 Jun-Jul;103(6-7):363-75.
- 27 Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. *J Clin Lipidol*. 2013 Sep-Oct;7(5):472-83.

- 28 Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. *Pharmacotherapy*. 2005 Aug;25(8):1035-43.
- 29 McGinnis BD, Olson KL, Delate TM, Stolcpart RS. Statin adherence and mortality in patients enrolled in a secondary prevention program. *Am J Manag Care*. 2009 Oct;15(10):689-95.
- 30 Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet*. 2016 Sep 8.
- 31 Sathasivam S, Lecky B. Statin induced myopathy. *Bmj*. 2008;337:a2286.
- 32 Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J*. 2015 May 1;36(17):1012-22.
- 33 Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. *Circulation*. 2013 Jan 1;127(1):96-103.
- 34 Alfircvic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. *Clin Pharmacol Ther*. 2014 Oct;96(4):470-6.
- 35 Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. *Ann Pharmacother*. 2010 Sep;44(9):1410-21.
- 36 Berglund E, Lytsy P, Westerling R. Adherence to and beliefs in lipid-lowering medical treatments: a structural equation modeling approach including the necessity-concern framework. *Patient Educ Couns*. 2013 Apr;91(1):105-12.
- 37 Gobel B, Zwart D, Hesselink G, et al. Stakeholder perspectives on handovers between hospital staff and general practitioners: an evaluation through the microsystems lens. *BMJ Qual Saf*. 2012 Dec;21 Suppl 1:i106-13.
- 38 Viktil KK, Blix HS, Eek AK, et al. How are drug regimen changes during hospitalisation handled after discharge: a cohort study. *BMJ Open*. 2012;2(e001461. doi:10.1136/bmjopen-2012-001461).
- 39 De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. *Br J Clin Pharmacol*. 2014 Oct;78(4):684-98.
- 40 Phillips B, Roberts C, Rudolph AE, et al. Switching statins: the impact on patient outcomes. *Br J Cardiol*. 2007;14(5):280-5.
- 41 Jacobson TA, Wertz DA, Kuznik A, Cziraky M. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. *Curr Med Res Opin*. 2013 Jul;29(7):773-81.
- 42 Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. *Patient Prefer Adherence*. 2012;6:323-9.
- 43 DiDonato KL, Liu Y, Lindsey CC, Hartwig DM, Stoner SC. Community pharmacy patient perceptions of a pharmacy-initiated mobile technology app to improve adherence. *Int J Pharm Pract*. 2015 Jan 9.
- 44 Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. *Eur Heart J*. 2008 Sep;29(17):2083-91.
- 45 Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. *Stroke*. 2007 Oct;38(10):2652-7.


## Figure legends


**Figure 1** A schematic of the study selection process.


## Figure 2 Cumulative survival curves

The cumulative survival curves compared suboptimal statin (green) and constant statin use (blue) group survival free from; **A**) major adverse cardiovascular events (MACE) and; **B**) all-cause mortality (ACM). Survival curves plotted until last event occurrence.









**Highlights**

- Deviation from high potency statin therapy is common early in secondary prevention
- Deviation can be by discontinuation, dose reduction, switching or non-adherence
- Muscular symptoms are associated with suboptimal statin use
- Statin discontinuation/non-adherence is associated with increased adverse outcomes
- Interventions to enhance statin use could improve secondary prevention outcomes